Key result
Rosuvastatin and omega-3 fatty acid exposure is linked to increased serum adiponectin levels.
Why the study?
The relationship between adiponectin serum levels and risk of coronary artery disease remains controversial, and the effects of rosuvastatin and omega-3 fatty acid on adiponectin in patients with insulin resistance and CAD were unclear.
Does rosuvastatin and/or omega-3 fatty acid improve adiponectin serum levels in patients with CAD and insulin resistance?
Observational (n=87)
Does rosuvastatin and/or omega-3 fatty acid improve adiponectin serum levels in patients with CAD and insulin resistance?
Rosuvastatin and/or omega-3 fatty acid may provide cardiometabolic protection by increasing adiponectin serum levels in patients with CAD and insulin resistance.
Answers are grounded in this paper and cite their sources.
Rosuvastatin or omega-3 may raise adiponectin in IR-CAD; leaves open clinical benefit pending randomized trials.
BACKGROUND: Adiponectin is an important adipocyte-related protein that has been postulated to participate in prevention of the development of metabolic syndrome. The relationship between adiponectin serum levels and risk of coronary artery disease (CAD) has been widely investigated and remains controversial. The aim of the present study was to evaluate the effects of rosuvastatin and/or omega-3 fatty acid on adiponectin serum levels in patients with insulin resistance (IR) and CAD. PATIENTS AND METHODS: This study involved 87 patients with CADs and IR of different etiology, the patients were divided into three groups; 24 patients on treatment with rosuvastatin, 22 patients on treatment with omega-3 fatty acid, 23 patients on treatment with omega-3 fatty acid and rosuvastatin, 18 patients were not previously or currently treated with either rosuvastatin or omega-3 fatty acid, those regarded as control patients. Anthropometric measures, adiponectin serum levels, and other biochemical parameters were assessed in each treated group. CONCLUSIONS: Rosuvastatin and/or omega-3 fatty acid lead to significant cardiometabolic protection through an increment in adiponectin serum levels.
No takes yet. Share an insight, caveat, or question.
Al‐kuraishy et al. (2016) conducted an observational in Coronary artery disease and insulin resistance (n=87). Rosuvastatin and/or omega-3 fatty acid vs. No previous or current treatment with rosuvastatin or omega-3 fatty acid was evaluated on Adiponectin serum levels and cardiometabolic profile (p=< 0.01). Rosuvastatin and/or omega-3 fatty acid exposure was associated with a significant increment in adiponectin serum levels.
Synapse has enriched 10 related papers. Consider them for comparative context: